Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization.

导出 LinkOut

翻译打印收藏纠错

作者： Triana,Amen ^[1] ; Daniel,Kaganovich ^[2]

作者单位： Department of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel. ; Alexander Grass Center for Bioengineering, Hebrew University of Jerusalem, Jerusalem, Israel. ^[1] Department of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel. ^[2]

关键词 Alzheimer’s FDA amyloid beta drug screen yeast

DOI 10.15698/mic2016.03.482

PMID 28362007

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览12

Microbial cell (Graz, Austria)

2016年3卷3期

97-100页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization.

Microbial cell (Graz, Austria)

相似文献

Microbial cell (Graz, Austria)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization.

Microbial cell (Graz, Austria)

相似文献

Microbial cell (Graz, Austria)

相关期刊

检索历史清除